Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Immucell (ICCC) Revenue (2016 - 2025)

Immucell's Revenue history spans 16 years, with the latest figure at $7.6 million for Q4 2025.

  • For Q4 2025, Revenue fell 1.61% year-over-year to $7.6 million; the TTM value through Dec 2025 reached $27.6 million, up 2.49%, while the annual FY2025 figure was $27.6 million, 4.34% up from the prior year.
  • Revenue reached $7.6 million in Q4 2025 per ICCC's latest filing, up from $5.5 million in the prior quarter.
  • In the past five years, Revenue ranged from a high of $8.1 million in Q1 2025 to a low of $3.4 million in Q1 2023.
  • Average Revenue over 5 years is $5.5 million, with a median of $5.4 million recorded in 2021.
  • Peak YoY movement for Revenue: plummeted 42.55% in 2023, then surged 110.58% in 2024.
  • A 5-year view of Revenue shows it stood at $5.4 million in 2021, then decreased by 28.16% to $3.9 million in 2022, then surged by 37.99% to $5.4 million in 2023, then skyrocketed by 43.63% to $7.8 million in 2024, then dropped by 1.61% to $7.6 million in 2025.
  • Per Business Quant, the three most recent readings for ICCC's Revenue are $7.6 million (Q4 2025), $5.5 million (Q3 2025), and $6.4 million (Q2 2025).